Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2002-08-01
2009-10-13
Noakes, Suzanne M. (Department: 1656)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
Reexamination Certificate
active
07601683
ABSTRACT:
Stable protein conformational isomers and methods for producing and isolating such isomers are disclosed. Methods of using such isomers, and products and compositions comprising such isomers are also disclosed.
REFERENCES:
patent: 6214366 (2001-04-01), Prusiner et al.
patent: 6214565 (2001-04-01), Prusiner et al.
patent: 6322802 (2001-11-01), Prusiner et al.
patent: 6900036 (2005-05-01), Chang et al.
patent: 2006/0018918 (2006-01-01), Chang
patent: 0588139 (1998-01-01), None
Chang, J-Y. Denatured States of Tick Anticoagulant Peptide. Jan. 1, 1999. The Journal of Biological Chemistry. 274, 1, 123- 128.
Chang, J-Y et al. Unfolding and Refolding of Cardiotoxin III Elucidated by Reversible Conversion of the Native and Scambled Species. 1998. Biochemistry. 37, 6745-6751.
Chang, J-Y et al. The Disulfide Folding Pathway of Potato Carboxypeptidase lnibitor. Sep. 2, 1994. The Journal of Biological Chemistry. 269, 35, 22087-22094.
Milner et al. Mutations in the B-domain of insulin-like growth factor-I influence the oxidative folding to yield products with modified biological properties. Biochemical Journal. 1995. vol. 308, pp. 865-871.
Clarke et al. Engineered Disulfide Bonds as Probes of the Folding Pathway of Barnase: Increasing the Stability Against the Rate of Denaturation. Biochemistry. 1993. vol. 32, pp. 4322-4329.
Cho et al. Thermostable Variants of Bovine Beta-Lactoglobulin. Protein Engineering. 1994. vol. 7, No. 2, pp. 263-270.
Chang, J-Y. Denatured States of Tick Anticoagulant Peptide. The Journal of Biological Chemistry. Jan. 1, 1999. vol. 274, No. 1, pp. 123-128.
Chang, J-Y et al. Unfolding and Refolding of Cardiotoxin III Elucidated by Reversible Conversion of the Native and Scambled Species. Biochemistry. 1998. vol. 37, pp. 6745-6751.
Chang, J-Y et al. The Disulfide Folding Pathway of Potato Carboxypeptidase Inibitor. Sep. 2, 1994. The Journal of Biological Chemistry. 269, 35, 22087-22094.
Chang et al. Production of disulfide-linked hirudin dimer by in vitro folding. FEBS Letters. 1993. vol. 336, No. 1, pp. 53-56.
Lu et al. Oxidative Folding of Murine Prion rPrP(23-231). European Journal of Biochemistry. 2001. vol. 268, pp. 3767-3773.
Wickner et al. Posttranslational Quality Control: Folding, Refolding and Degrading Proteins. Science. Dec. 3, 1999. vol. 286, pp. 1888-1893.
U.S. Appl. No. 11/177,509, Chang, filed Jul. 8, 2005, Non-Final Rejection (11 pages), Dated Apr. 10, 2007.
U.S. Appl. No. 11/177,509, Chang, filed Jul. 8, 2005, Amendment and Response to Office Action (32 pages), Dated Aug. 8, 2007.
U.S. Appl. No. 11/177,509, Chang, filed Jul. 8, 2005, Notice of Appeal (2 pages), Dated Apr. 29, 2008.
U.S. Appl. No. 11/177,509, Chang, filed Jul. 8, 2005, Amendment and Response to Final Office Action (9 pages), Dated Apr. 29, 2008.
Aguzzi, A. et al., “Progress and problems in the biology, diagnostics, and therapeutics of prion disease,”J. Clin. Invest., 114(2): 153-160 (2004).
Baker, J.T., “Material Safety Data Sheet for 2-Mercaptoethanol,”MSDANo. M1209 http://jtbaker.com/msds/englishhtml/m1209.htm (Aug. 10, 2004).
Baker, J.T., “Material Safety Data Sheet for 2-Mercaptoethanol,”MSDANo. M1209 http://jtbaker.com/msds/englishhtml/m1209.htm (Jul. 3, 2007).
Balter, M., “Disease Research: Prions: A lone killer or a Vital Accomplice,”Science, 286(5440): 660-662 (1999).
Barrick, D. and Baldwin, R. L., “The molten globule intermediate of apomyoglobin and the process of protein folding,”Protein Sci., 2: 869-876 (1993).
Basler, K. et al., “Scrapie and Cellular PrP Isoforms Are Encoded by the Same Chromosomal Gene,”Cell, 46: 417-428 (1986).
Bendheim, P.E. and Potempska, A., “Purification and Partial Characterization of the Normal Cellular Homologue of the Scrapie Agent Protein,”J. Infect. Dis., 158(6): 1198-1208 (1988).
Bendheim, P.E. et al., “Nearly ubiquitous tissue distribution of the scrapie agent precursor protein,”Neurology, 42: 149-156 (1992).
Bessen, R.A. et al., “Non-genetic propagation of strain-specific properties of scrapie prion protein,”Nature, 375: 698-700 (1995).
Biere, A.L. et al., “Parkinson's Disease-associated α-Synuclein Is More Fibrillogenic than β- and γ-Synuclein and Cannot Cross-seed Its Homologs,”J Biol Chem., 275(44): 34574-34579 (2000).
Blanco-Aparicio et al., “Potato Carboxypeptidase Inhibitor, a T-knot Protein, Is an Epidermal Growth Factor Antagonist That InhibitsTtumor Cell Growth,”J. Biol. Chem., 273(20): 12370-12377 (1998).
Blundell, T.L., “Structure-based drug design,”Nature, 384(7): 23-26 (1996).
Broach, J.R. and Thorner, J., “High-throughput screening for drug discovery,”Nature, 384(7): 14-16 (1996).
Brown, H.R. et al., “The mRNA encoding the scrapie agent protein is present in a variety of non-neuronal cells,”Acta Neuropathol., 80: 1-6 (1990).
Campbell, I.D. and Bork, P., “Epidermal growth factor-like modules,”Curr. Opin. Struct. Biol., 3: 385-392 (1993).
Cashman, N.R. et al., “Cellular Isoform of the Scrapie Agent Protein Participates in Lymphocyte Activation,”Cell, 61: 185-192 (1990).
Caughey, B. et al., “Strain-dependent Differences in β-Sheet Conformations of Abnormal Prion Protein,”J. Biol. Chem., 273(48): 32230-32235 (1998).
Caughey, B. et al., “Methods for Studying Prion Protein (PrP) Metabolism and the Formation of Protease-Resistant PrP in Cell Culture and Cell-Free Systems,”Mol. Biotechnol., 13: 45-55 (1999).
Chang, J-Y. and Li, L., “The Structure Of Denatured α-Lactalbumin Elucidated by the Technique of Disulfide Scrambling,”J. Biol. Chem., 276(13): 9705-9712 (2001).
Chang, J-Y. et al., “Analysis of the extent of unfolding of denatured insulin-like growth factor,”Protein Sci., 8: 1463-1468 (1999).
Chang, J-Y. and Li, L., “The Disulfide Structure of Denatured Epidermal Growth Factor: Preparation of Scrambled Disulfide Isomers,”J. Protein. Chem., 21(3): 203-213 (2002).
Chesebro, B. et al., “Identification of scrapie prion protein-specific mRNA in scrapie-infected and uninfected brain,”Nature, 315: 331-333 (1985).
Clackson, T. et al., “Making antibody fragments using phage display libraries,”Nature, 352: 624-628 (1991).
Cohen, F.E. and Prusiner, S.B., “Pathologic Conformations Of Prion Proteins,”Annu. Rev. Biochem., 67: 793-819 (1998).
Conway, K.A. et al., “Accelerated in vitro fibril formation by a mutant α-synuclein linked to early-onset Parkinson disease,”Nat. Med., 4(11): 1318-1320 (1998).
Cwirla, S.E. et al., “Peptides on phage: A vast library of peptides for identifying ligands,”Proc. Natl. Acad. Sci. USA, 87: 6378-6382 (1990).
Daggett, V., “Structure-function aspects of prion proteins,”Curr. Opin. Biotechnol., 9: 359-365 (1998).
Dill, K.A. and Shortle, D., “Denatured States of Proteins,”Annu. Rev. Biochem., 60: 795-825 (1991).
Dobson, C.M., “Protein misfolding, evolution and disease,”TIBS, 24: 329-332 (1999).
Donne, D.G., et al., “Structure of the recombinant full-length hamster prion protein PrP(29-231): The N terminus is highly flexible,”Proc. Natl. Acad. Sci. USA, 94: 13452-13457 (1997).
Doolittle, R.F. et al., “Computer-based characterization of epidermal growth factor precursor,”Nature, 307: 558-560 (1984).
Esch, F.S. et al., “Cleavage of Amyloid # Peptide During Constitutive Processing of Its Precursor,”Science, 248(4959): 1122-1124 (1990).
Foster, B.A. et al., “Pharmacological Rescue of Mutant p53 Conformation and Function,”Science, 286: 2507-2510 (1999).
Frand, A.R. et al., “Pathways for protein disulphide bond formation,”Trends Cell Biology, 10(5): 203-210 (2000).
Gajdusek, D.C., “Unconventional Viruses and the Origin and Disappearance of Kuru,”Science, 197(4307): 943-960 (1977).
Galfrè, G. and Milstei
Ballard Spahr Andrews & Ingersoll LLP
Board of Regents of the University of Texas System
Noakes Suzanne M.
LandOfFree
Protein conformational isomers, methods of making, methods... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Protein conformational isomers, methods of making, methods..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Protein conformational isomers, methods of making, methods... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4102142